The medtech firm plans to launch its next flagship patch-pump in 2027, and its first fully closed loop system for Type 2 diabetes in 2028.

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com ...

Introduction Post-induction hypotension (PIH) is a critical concern in elderly surgical patients and is associated with adverse postoperative outcomes. This trial aims to compare the effects of ...

First up is an ode to an old Nashville culinary classic, the spiced round. Now, there are a lot of things I miss about our erstwhile Scene colleague JR Lind, but one of my favorite things about him ...

Good morning, and welcome to the Jefferies 2025 Healthcare Conference. It's my pleasure now to introduce David Kirn, CEO; and Chris Simms, Chief Commercial Officer of 4D Molecular Therapeutics. All ...

Q3 2025 Earnings Call November 20, 2025 8:30 AM ESTCompany ParticipantsAlbert Friesen - Founder, CEO & Chairman of ...

Turkey, stuffing and cranberry prices are all lower, but skip the yams. Sweet potato prices have skyrocketed. Liz Matthews is considered the GOAT of new product ideas, testing hundreds to develop ...

Modular Medical (Nasdaq:MODD) announced that it has submitted its next-generation Pivot insulin pump to the FDA for clearance.